2016
Continuous Home Care Reduces Hospice Disenrollment and Hospitalization After Hospice Enrollment
Wang SY, Aldridge MD, Canavan M, Cherlin E, Bradley E. Continuous Home Care Reduces Hospice Disenrollment and Hospitalization After Hospice Enrollment. Journal Of Pain And Symptom Management 2016, 52: 813-821. PMID: 27697564, PMCID: PMC5154927, DOI: 10.1016/j.jpainsymman.2016.05.031.Peer-Reviewed Original ResearchConceptsHospice disenrollmentHospice enrollmentPatient characteristicsContinuous home careCHC utilizationMinority of patientsHome careMore comorbiditiesMultivariable analysisMultivariable modelHospice carePatientsHospitalizationService MedicareHospice agenciesHospiceDisenrollmentExpensive careStudy periodCareEnrollmentAssociationComorbiditiesCancerAssociations Between End-of-Life Cancer Care Patterns and Medicare Expenditures.
Wang SY, Hall J, Pollack CE, Adelson K, Davidoff AJ, Long JB, Gross CP. Associations Between End-of-Life Cancer Care Patterns and Medicare Expenditures. Journal Of The National Comprehensive Cancer Network 2016, 14: 1001-8. PMID: 27496116, PMCID: PMC5577560, DOI: 10.6004/jnccn.2016.0107.Peer-Reviewed Original ResearchConceptsDay of deathLife care expendituresLife careIntensive endCancer decedentsIntensive care unit admissionCare expendituresLife care interventionsCare unit admissionEmergency department visitsSEER-Medicare databaseLast monthProportion of decedentsHospital referral regionsExpenditure differencesHospital deathICU admissionUnit admissionDepartment visitsHospice enrollmentIntensive careHighest quintileLater chemotherapyHospice useLowest quintile
2015
Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base
Killelea BK, Yang VQ, Wang SY, Hayse B, Mougalian S, Horowitz NR, Chagpar AB, Pusztai L, Lannin DR. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base. Journal Of Clinical Oncology 2015, 33: 4267-4276. PMID: 26598753, DOI: 10.1200/jco.2015.63.7801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsAsianBiomarkers, TumorBlack or African AmericanBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, LobularChemotherapy, AdjuvantComorbidityDatabases, FactualFemaleHispanic or LatinoHumansInsurance CoverageInsurance, HealthMiddle AgedNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTreatment OutcomeTriple Negative Breast NeoplasmsUnited StatesWhite PeopleConceptsPathologic complete responseNational Cancer Data BaseNeoadjuvant chemotherapyBreast cancerEstrogen receptorWhite womenPositive tumorsAsian womenHuman epidermal growth factor receptor 2HER2-positive breast cancerEpidermal growth factor receptor 2Timing of chemotherapyClinical T stageGrowth factor receptor 2Triple-negative tumorsPatient's zip codeHigh-grade tumorsRacial differencesZip codesFactor receptor 2Chemotherapy useComorbidity indexComplete responseT stageGrade tumorsThe Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer
Xu X, Herrin J, Soulos PR, Saraf A, Roberts KB, Killelea BK, Wang SY, Long JB, Wang R, Ma X, Gross CP. The Role of Patient Factors, Cancer Characteristics, and Treatment Patterns in the Cost of Care for Medicare Beneficiaries with Breast Cancer. Health Services Research 2015, 51: 167-186. PMID: 26119176, PMCID: PMC4722219, DOI: 10.1111/1475-6773.12328.Peer-Reviewed Original ResearchConceptsBreast cancer careHospital referral regionsCancer careMedicare expendituresBreast cancerRadiation therapyTreatment factorsMean Medicare expendituresEnd Results-MedicareSpecific treatment modalitiesContribution of patientCost of careHighest spending quintilePatient factorsTreatment patternsTumor characteristicsCancer characteristicsTreatment modalitiesReferral regionsMedicare beneficiariesQuintilePatientsCancerCareTherapy
2014
Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival
Wang SY, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP, Chen J. Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Research And Treatment 2014, 146: 411-419. PMID: 24951268, DOI: 10.1007/s10549-014-3029-0.Peer-Reviewed Original ResearchConceptsCardiovascular eventsEarly discontinuationTrastuzumab treatmentCause mortalityTrastuzumab therapyTrastuzumab discontinuationBreast cancerCox proportional hazards modelContinuous trastuzumab treatmentAdverse cardiovascular eventsPopulation-based cohortFemale Medicare beneficiariesHigher mortality riskProportional hazards modelNon-significant increaseCardiovascular complicationsOlder patientsOverall survivalHeart failureAtrial fibrillationDiscontinuationMortality riskOlder womenMedicare beneficiariesHazards modelExamining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer
Sen S, Wang SY, Soulos PR, Frick KD, Long JB, Roberts KB, Yu JB, Evans SB, Chagpar AB, Gross CP. Examining the Cost-Effectiveness of Radiation Therapy Among Older Women With Favorable-Risk Breast Cancer. Journal Of The National Cancer Institute 2014, 106: dju008. PMID: 24598714, PMCID: PMC3982782, DOI: 10.1093/jnci/dju008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBrachytherapyBreast NeoplasmsComorbidityCost-Benefit AnalysisFemaleHealth ExpendituresHumansLife ExpectancyMedicareNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeQuality-Adjusted Life YearsRadiotherapy, Intensity-ModulatedRisk AssessmentRisk FactorsSampling StudiesSEER ProgramUnited StatesConceptsExternal beam radiation therapyIncremental cost-effectiveness ratioQuality-adjusted life yearsBreast cancerOlder womenRadiation therapyEnd Results-Medicare databaseRisk breast cancerBeam radiation therapyCost-effectiveness ratioNewer radiation therapy modalitiesQuality of lifeRadiation therapy modalitiesLocal recurrenceTrial criteriaRT modalityTherapy modalitiesLife yearsCancerIncremental costTherapyWomenBaseline stateNew modality